← Back to Screener
Neuronetics, Inc. Common Stock (STIM)
Price$1.58
Favorite Metrics
Price vs S&P 500 (26W)-57.85%
Price vs S&P 500 (4W)-11.56%
Market Capitalization$109.46M
All Metrics
Book Value / Share (Quarterly)$0.32
P/TBV (Annual)22.35x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)31.76%
Cash Flow / Share (Quarterly)$-0.31
Price vs S&P 500 (YTD)-1.24%
Gross Margin (TTM)48.48%
Net Profit Margin (TTM)-26.15%
EPS (TTM)$-0.60
10-Day Avg Trading Volume2.37M
EPS Excl Extra (TTM)$-0.60
Revenue Growth (5Y)24.81%
EPS (Annual)$-0.59
ROI (Annual)-44.22%
Gross Margin (Annual)48.48%
Net Profit Margin (5Y Avg)-48.04%
Cash / Share (Quarterly)$0.41
Revenue Growth QoQ (YoY)85.73%
ROA (Last FY)-27.55%
Revenue Growth TTM (YoY)99.17%
EBITD / Share (TTM)$-0.41
ROE (5Y Avg)-104.40%
Operating Margin (TTM)-21.08%
Cash Flow / Share (Annual)$-0.31
P/B Ratio4.89x
P/B Ratio (Quarterly)4.22x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.99x
Net Interest Coverage (TTM)-3.65x
ROA (TTM)-27.68%
EPS Incl Extra (Annual)$-0.59
Current Ratio (Annual)2.02x
Quick Ratio (Quarterly)1.68x
3-Month Avg Trading Volume1.96M
52-Week Price Return-62.33%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.06
P/S Ratio (Annual)0.73x
Asset Turnover (Annual)1.05x
52-Week High$4.85
Operating Margin (5Y Avg)-43.93%
EPS Excl Extra (Annual)$-0.59
CapEx CAGR (5Y)1.87%
26-Week Price Return-49.10%
Quick Ratio (Annual)1.68x
13-Week Price Return-19.77%
Total Debt / Equity (Annual)2.94x
Current Ratio (Quarterly)2.02x
Enterprise Value$147.13
Revenue / Share Growth (5Y)-2.85%
Asset Turnover (TTM)1.06x
Book Value / Share Growth (5Y)-24.65%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)17.92x
Pretax Margin (Annual)-26.24%
Cash / Share (Annual)$0.41
3-Month Return Std Dev112.72%
Gross Margin (5Y Avg)69.69%
Net Income / Employee (TTM)$-0
ROE (Last FY)-174.27%
Net Interest Coverage (Annual)-3.65x
EPS Basic Excl Extra (Annual)$-0.59
Receivables Turnover (TTM)7.49x
Total Debt / Equity (Quarterly)2.94x
EPS Incl Extra (TTM)$-0.60
Receivables Turnover (Annual)7.49x
ROI (TTM)-43.98%
P/S Ratio (TTM)0.73x
Pretax Margin (5Y Avg)-48.06%
Revenue / Share (Annual)$2.26
Tangible BV / Share (Annual)$0.06
Price vs S&P 500 (52W)-97.43%
Year-to-Date Return2.90%
5-Day Price Return2.16%
EPS Normalized (Annual)$-0.59
ROA (5Y Avg)-27.70%
Net Profit Margin (Annual)-26.15%
Month-to-Date Return-2.07%
Cash Flow / Share (TTM)$-1.10
EBITD / Share (Annual)$-0.41
Operating Margin (Annual)-21.08%
LT Debt / Equity (Annual)2.94x
ROI (5Y Avg)-39.01%
LT Debt / Equity (Quarterly)2.94x
EPS Basic Excl Extra (TTM)$-0.60
P/TBV (Quarterly)22.35x
P/B Ratio (Annual)4.22x
Inventory Turnover (TTM)17.92x
Pretax Margin (TTM)-26.24%
Book Value / Share (Annual)$0.32
Price vs S&P 500 (13W)-22.64%
Beta0.87x
Revenue / Share (TTM)$2.17
ROE (TTM)-138.87%
52-Week Low$0.80
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
STIMNeuronetics, Inc. Common Stock | 0.73x | 24.81% | 48.48% | -21.08% | $1.58 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Neuronetics Inc is a medical device company specializing in transcranial magnetic stimulation (TMS) therapy for psychiatric disorders. Its flagship product, the NeuroStar Advanced Therapy System, is a non-invasive, office-based treatment that uses MRI-strength magnetic fields to stimulate brain regions associated with mood regulation. NeuroStar is approved to treat major depressive disorder (MDD) and offers an alternative to conventional psychiatric therapies that may have significant side effects or efficacy limitations.